ArticlePlastic and reconstructive surgery. Global open2025
Considerations for the Use of Glucagon-like Peptide-1 Medications for Obesity in a Plastic Surgery Setting.
Article in Plastic and reconstructive surgery. Global open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Combined Airway and Bariatric Surgery for Obesity Hypoventilation Syndrome: Feasibility and Early Outcomes-A Prospective Observational Cohort Study.Journal of clinical medicine · 2026Article
- Mapping the Impact of Glucagon-Like Peptide-1 Receptor Agonists on Aesthetic and Reconstructive Plastic Surgery: A Bibliometric Analysis of the 50 Most Cited Studies.Aesthetic plastic surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, there has been great interest among the medical community and general public in a new generation of medications for treating obesity. Likely due to this interest, there have been anecdotal reports of plastic surgeons beginning to prescribe these medications in their practices. This Special Topic article provides a brief overview of obesity and its evidence-based treatments, including these newer medications. Particular emphasis is placed on the growing consensus that obesity is a chronic disease that contributes to numerous other comorbidities and requires sustained treatment. Plastic surgeons who are interested in using newer obesity medications in their practices may wish to consider the need for additional training to ensure that they are optimizing patient welfare, guarding against harm, and providing care consistent with clinical guidelines and recommended best practices of obesity medicine.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.